Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt

The deal is done. After undoubtedly tense negotiations, the heads of terms for the new Voluntary Scheme for Branded Medicines Pricing and Access have just been published, and although some...

- PMLiVE

Bad news for BMS as Keytruda kidney cancer combo approved

Opdivo and Yervoy combination will be squeezed

- PMLiVE

New biotech accelerator launched in Cambridge, UK

Start Codon aims to invest in 50 start-up companies over the next five years

- PMLiVE

Genfit claims FDA breakthrough status for liver disease drug

Elafibranor up for speedy US review

- PMLiVE

With Spiriva under pressure, Boehringer moves to bolster pipeline

Forges alliance with PureTech Health

- PMLiVE

Mereo’s shareholders back OncoMed takeover

Deal expected to go through next week

Lucid Group announces the appointment of new CFO

Lucid Group continues to build its infrastructure in line with its ambitious growth plans by appointing Michael Joyce as Chief Financial Officer (CFO).Michael has considerable experience as a CFO and...

Lucid Group Communications Limited

- PMLiVE

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality

How pharma is progressing their commitment in patient engagement

- PMLiVE

Q&A: Niels Lund

PME interviews Novo Nordisk's Vice President, Health Advocacy

- PMLiVE

Novartis makes case for gene therapy Zolgensma in SMA

New data revealed ahead of FDA review

- PMLiVE

Adding different perspectives to scientific communications at Porterhouse Medical

Porterhouse Medical Group is delighted to announce that, once again, we have strengthened our scientific services team – this time with three new associate medical writers who, with different scientific...

Porterhouse Medical Group

- PMLiVE

Stem cell transplant firms Kiadis and CytoSen join forces

Acquires an NK cell based platform with the deal

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links